He was treated with a further course of acyclovir (1 5 g/m2 surface area/day) followed, in view of the possibility of a resistant organism, by a course of intravenous vidarabine. On this regime his fever, conscious level, and hemiplegia improved. After discharge he is left with a mild right facial weakness and a mild persisting dysphasia.
biphasic course. The secondary deterioration may be due to a resurgence of the viral infection and calls into question the adequacy of current treatment regimens for HSE. Alternatively, a postinfectious neuroallergic process may be active in which case immunomodulatory treatment might be more appropriate than further antiviral treatment.
There are a number of reports of adults who experienced herpes simplex encephalitis (HSE), that was proved at biopsy, four days to two months after satisfactory response to antiviral treatment.'-3 Until recently, only three paediatric cases of relapse have been described' of which two4 5 were thought to represent postinfectious neuroallergic phenomena. The third case occurred after herpes simplex virus (HSV) type 2 infection in a 6 week old baby and was therefore probably of congenital origin. These have now been supplemented by the description of a further five cases in whom there was evidence to suggest a postinfectious phenomenon (M A Carpentier-Barthez et al, paper At discharge he was visually inattentive with a right hemiplegia and a gradually resolving left hemichorea.
Discussion
The biphasic course of the illness in these children may be the result of a resurgence of the viral infection, a postinfectious neuroallergic phenomenon, or a second unrelated and coincidental illness. Extensive investigation has not showed an alternative disease entity. Immunodeficiency seems unlikely as of the two children investigated immunologically only one showed any abnormalities and these were not thought sufficient to explain the clinical course. Furthermore in none of the three children has there been a preceding or succeeding history suggestive of immunodeficiency.
The possibility of viral relapse was not supported by direct evidence of the presence of virus in the second phase of the illness as none of the children had a brain biopsy and the polymerase chain reaction for identification of HSV in the cerebrospinal fluid was not available. The serological findings in case 2 did not show a second rise in titres to support resurgent infection. However there are precedents for a resurgence of HSV that has been proved at biopsy in adults. 1-3 The good clinical response to a second course of antiviral treatment in case 1 is in favour of this mechanism.
Such a hypothesis calls into question the adequacy of the initial treatment. Case 1 had dexamethasone in addition to acyclovir as part of the treatment for his initial illness and it is possible that this may have had an immuno-suppressant effect. Alternatively the dose and/or duration of the initial treatment may have been inadequate. All three cases were treated with conventionally adequate HSE regimens. It may be that where there is a confirmed diagnosis of HSE, a 14 day course of high dose acyclovir is more appropriate than a 10 day one.
The alternative postinfectious neuroallergic hypothesis was the presumed mechanism in the seven other non-neonatal paediatric relapses described to date as the specimens from 
